), a global leader in medical devices used in critical care and
surgery, revealed that its Weck EFx Endo Fascial Closure System has
been chosen by the Society of Laparoendoscopic Surgeons (SLS) as
one of its Innovations of the Year for 2012. The company will be
presented the award at the SLS Annual Meeting to be held in Boston,
Massachusetts from September 5-8.
This marks the second occasion when Teleflex's offering has been
chosen for the celebrated award. Earlier, the company's Weck
Hem-o-lok Auto Endo5 Ligation System had been recognized as one of
the most innovative products for utilization in minimally invasive
According to the company, the Weck EFx System will bolster its
existing potential in the arena of laparoscopic surgery. The system
has already received the 510(k) clearance from the U.S. Food and
Drug Administration (FDA) and awaits the CE Mark approval in
The Weck EFx System will improve standards of patient care and
thereby upgrade clinical outcomes. The system comes with a unique
design for port site closure to reduce complications as well as
expenses related to port-site herniation. It allows reproducible
closure of the fibrous, connective tissues for different body types
and offers a guarded surgical suture.
Teleflex, headquartered in Limerick, Pennsylvania, might venture
into novice end markets on the back of the Weck EFx System. The
company's strategy of developing new, innovative products is
yielding proven results as reflected in the 94 basis points
contribution by new product introductions to Teleflex revenues in
the most recent quarter.
Teleflex's move to divest OEM Orthopedic division along with its
objective of portfolio expansion should help improve its financial
performance in the long run. The proceeds from the sale of the OEM
Orthopedic business, coupled with Teleflex's ability to generate
sufficient cash flow from operations will allow it to exploit
), which operate in similar business segments, present a tough
competitive landscape for Teleflex. The demand for its products is
susceptible to healthcare reimbursement systems in the domestic as
well as the international market. Additionally, the company
operates in a stringent regulatory environment.
Teleflex currently retains a Zacks #4 Rank, which translates
into a short-term Sell rating.
BARD C R INC (BCR): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.